glp 1 efficacy comparison Comparing GLP-type therapies for weight loss in those without diabetes. Two glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual agonist (#tirzepatide) have been FDA-approved for #weightloss in adults Pharma Competitive Intelligence in One

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Cooley BC, Nevado J, Mellad J, Yang D, St Hilaire C, Negro A, Fang F, Chen G, San H, Walts AD

Abstract Platinum-based chemotherapeutic agents constitute the cornerstone of treatment for a wide range of solid tumors

If you have ever noticed that the benefits of these peptides fade after a few months, or that your progress plateaus, there is a biological reason behind it

: 1-2 1 2

Bone Density Decline: Clinical trials have shown that one year of semaglutide therapy can reduce hip bone mineral density (BMD) by approximately 2.6% and lumbar spine density by 2.1%